Patricia Shifflett
Senior Vice President & Chief Business Officer
Contact
PatriciaShifflett@westat.comOverview
Patricia Shifflett, MS, serves on the Westat Board of Directors and is Senior Vice President and Chief Business Officer. In this role, she ensures high-quality technical delivery, drives business growth, and partners with the Chief Solutions Officer to advance innovation and maximize client impact.
Shifflett brings more than 30 years of experience managing research and evaluation efforts at the federal, state, and local levels. At Westat, she most recently led the health sector, overseeing research, evaluation, and technical assistance programs for HHS. Previously, she has held senior leadership positions at professional services firms and nonprofit organizations
She is widely recognized for her work in infectious and chronic disease prevention and control and has published on special populations, including pregnant women, children, healthcare providers, and older adults.
Education
- MS, Organization and Management, Capella University School of Business
- BS, Nursing, Westminster College
-
Opioid prescription and diabetes among Medicare beneficiaries
196,
Diabetes Research and Clinical Practice
January 2023
S.S. Casagrande, A.Z. Beccera, Keith Rust, C.C. Cowie
DOILink for: Opioid prescription and diabetes among Medicare beneficiaries -
Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry
European Urology
January 2023
F. Chen, R.K. Madduri, A.A. Rodriguez, B.F. Darst, A. Chou, X. Sheng, A. Wang, et al.
DOILink for: Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry -
Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma
Blood
January 2022
J.E. Flerlage, J.R. Myers, J.L. Maciaszek, N. Oak, S.R. Rashkin, Y. Hui, Y.-D. Wang, et al.
DOILink for: Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma